Omnicell announces the expansion of its IV compounding service, an alternative to outsourcing. The service comprises updated technology, clinical expertise, operational support, and workflow/analytics to address challenges in sterile compounding. To enhance the service, Omnicell has added expert pharmacist consultants, best practice operating models, and a library of scientific data, including cGMP stability studies. These additions aim to streamline adoption and optimize performance, facilitate better production planning and staffing, establish beyond-use-dating programs, and increase financial return to customers.

Omnicell